[CAS NO. 1001908-89-9] SRT2183
PRODUCTS SPECIFICATIONS [1001908-89-9]
DESCRIPTION [1001908-89-9]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 468.57 |
| Molecular Formula | C27H24N4O2S |
| SMILES | O=C(NC1=C(C2=CN3C(SC=C3CN4CC[C@@H](O)C4)=N2)C=CC=C1)C(C=C5)=CC6=C5C=CC=C6 |
2 Publications Citing Use of MCE
Summary
IC50 & Target
|
SIRT1 0.36 μM (EC1.5) |
In Vitro
SRT 2183 (1-10 μM; 24-72 hours) inhibits the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner
[2]
.
SRT 2183 (5-10 μM in Reh cells; 10 μM in Ly3 cells; 24 hours) induces expression of DNA-damage response genes associated with accumulation of phospho-H2A.X levels
[2]
.
SRT2183 inhibits RANKL-induced osteoclast differentiation, fusion and resorptive capacity without affecting osteoclast survival
[3]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [2]
| Cell Line: | Reh cells, Nalm-6 cells (pre-B acute lymphoblastic leukemia (ALL) cell lines) |
| Concentration: | 1 μM, 5 μM, 10 μM |
| Incubation Time: | 24 hours, 48 hours, 72 hours |
| Result: | Inhibited the growth of Reh and Nalm-6 cells in a time- and dose-dependent manner. The IC 50 (median inhibition concentration) values for SRT 2183-mediated inhibition of proliferation at 48 h are approximately 8.7 μM for Reh cells and approximately 3.2 μM for Nalm-6 cells. |
Western Blot Analysis [2]
| Cell Line: | Reh cells, Ly3 cells |
| Concentration: | 5μM and 10μM (Reh cells); 10μM (Ly3 cells) |
| Incubation Time: | 24 hours |
| Result: | Induced accumulation of phospho-H2A.X in Reh as well as in Ly3 cells. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 250 mg/mL ( 533.54 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1342 mL | 10.6708 mL | 21.3415 mL |
| 5 mM | 0.4268 mL | 2.1342 mL | 4.2683 mL |
| 10 mM | 0.2134 mL | 1.0671 mL | 2.1342 mL |
-
1.
References
- [1] Milne JC, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29; 450(7170): 712–716.
- [2] Scuto A, et al. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells. Cell Death Dis. 2013 May; 4(5): e635.
- [3] Gurt I, et al. The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391.